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in the FACT-P total score of -9.68 (95% CI: [-16.10; -3.27]); pathological bone fractures 
and radiation or surgery to bone determined changes in FACT-P total score of -7.61 
(95% CI: [-16.79; 1.56]) and -6.68 (95% CI: [-10.25; -3.11]), respectively. The standardized 
effect size was moderate (any SRE: -0.32; spinal cord compression: -0.49; pathological 
bone fracture: -0.35; radiation or surgery to bone: -0.30). ConClusions: Consistent 
with previous analyses in metastatic prostate cancer [Weinfurt K.P., et al. Annals of 
Oncology 2005;16: 579–584], our findings demonstrate that SREs lead to significant 
functional declines in patients’ daily lives. Therefore, any therapy reducing or delaying 
the occurrence of SREs should also reduce the effects of SREs on HRQOL.
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objeCtives: The rates of adverse events (AEs) are an important component of 
chemotherapy cost effectiveness. However, AE rates in clinical practice are diffi-
cult to obtain. This study aimed to determine whether Australian administrative 
data could identify the incidence of selected chemotherapy AEs. Methods: The 
Elements of Care study (EoC) was a prospective cohort of individuals in New South 
Wales undergoing chemotherapy for breast, colorectal or lung cancer. Primary 
data, including AEs experienced, was collected through questionnaires and medi-
cal record review. Linked administrative data of prescriptions and medical services 
for each participant were available from the Pharmaceutical Benefits Scheme (PBS) 
and Medicare Benefits Schedule (MBS). This data was used to identify if an indi-
vidual was treated for one of the selected AEs (diarrhoea, vomiting, anaemia and 
neutropenia) in the three days after a chemotherapy dose. These proxy-identified AE 
rates were compared with the self-reported AE rates using 2x2 contingency tables, 
with significance of any differences calculated using odds ratios and chi-square 
statistics. Results: There were 482 individuals in EoC. The proxy identified much 
lower rates of AEs than were self-reported, capturing 30% of self-reported cases 
of nausea and vomiting, 1.3% of self-reported diarrhoea, and less than 1% of self-
reported anaemia and neutropenia. Additional analyses did not identify a pattern 
in the grade of AEs or type of treatment received that the proxy was more likely 
to identify. ConClusions: Overall there was poor concordance between the two 
measures of AE rates. This may be due to low treatment rates for AEs, poor capturing 
of AE treatments by the proxy, or over-reporting of adverse event by participants. 
Regardless, it would appear that administrative data such as the MBS and PBS are 
not suitable for estimating the incidence of AEs in clinical practice, and bottom up 
data collection techniques such as EoC are essential.
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objeCtives: To evaluate the burden of skin cancer among U.S. veteran 
patients. Methods: Patients diagnosed with skin cancer were identified (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis code 
232.xx) using the Veterans Health Administration (VHA) Medical SAS datasets from 
October 1, 2009 to September 30, 2011. The first diagnosis date was defined as the index 
date. A comparison group of patients without skin cancer of the same age, region, gen-
der and index year were identified and matched on baseline Charlson Comorbidity 
Index with a randomly chosen index date to minimize selection bias. Patients in both 
groups were required to be at least 18 years old and have 1 year continuous health plan 
enrollment pre- and post-index date. Follow-up health care costs and utilizations were 
compared between the two groups after using 1:1 propensity score matching adjust-
ing baseline characteristics. Results: A total of 12,504 patients were identified for the 
skin cancer and comparison cohorts. After 1:1 propensity score matching, each group 
included 4,400 patients with well-balanced baseline demographic and clinical charac-
teristics. Patients diagnosed with skin cancer had higher percentages of inpatient (5.75% 
vs. 2.64%, p< 0.01), emergency room (11.89% vs. 6.50%, p< 0.01), physician office (99.95% 
vs. 66.70%, p< 0.01), outpatient (99.95% vs. 67.41%, p< 0.01), and pharmacy visits (91.89% 
vs. 71.30%, p< 0.01). Patients in the skin cancer cohort also incurred higher expenditures 
in inpatient ($1,494 vs. $555, p< 0.01), emergency room ($108 vs. $60, p< 0.01), physician 
office ($4,486 vs. $1,480, p< 0.01), outpatient ($4,780 vs. $1,639) and pharmacy visits ($707 
vs. $429, p< 0.01) than patients in the comparison group. ConClusions: Study results 
suggest that cancer patients diagnosed with skin cancer incurred significantly higher 
costs and health care resources compared to patients without.
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objeCtives: To examine the economic burden and health care utilizations of 
colorectal cancer patients in the U.S. veteran population. Methods: A retrospec-
tive database analysis was performed using the Veterans Health Administration 
Medical SAS datasets (01OCT2008-30SEP2012). Patients (≥ 18 years of age) diagnosed 
with colorectal cancer (International Classification of Disease 9th Revision Clinical 
Modification ICD-9-CM codes 153.xx, 154.xx) were identified. The first diagnosis 
date was designated as the index date. A comparator group was created by cat-
egorizing patients without colorectal cancer but of the same age, region, gender 
and index year, and matching them by baseline Charlson Comorbidity Index. The 
index date for the comparison group was selected randomly to minimize selection 
bias. Continuous medical and pharmacy benefits for 1 year pre- and 1 year post-
index date were required. One-to-one propensity score matching (PSM) was used to 
compare the health care costs and utilizations during the follow-up period between 
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objeCtives: Notable side effects of abiraterone for advanced prostate cancer are 
oedema, hypertension, and hypokalemia, constituting a mineralocorticoid excess 
syndrome (MES). Although abiraterone is co-administered with prednisone to 
minimise MES symptoms, they remain a burden requiring concomitant therapies 
to manage each toxicity and/or treatment with costly mineralocorticoid receptor 
antagonists. A literature review was conducted to assess the impact of MES symp-
toms on health-related quality of life (HRQoL) and health care costs in patients 
across a number of disease areas. Methods: Outside prostate cancer, MES is a 
broad syndrome which is best characterised as bilateral primary aldosteronism 
(PA). Electronic databases were searched for data on the economic and humanistic 
burden of MES (or its symptoms in combination) and/or PA. Results: Even though 
no studies were identified in a specific prostate cancer population, nine studies 
found humanistic burden and three of the economic burden related to MES (PA) in 
the literature. Patients with MES (PA) had significantly impaired HRQoL (measured 
by SF36 and SF12) compared with the general population, especially on physical 
domains, general health perceptions, and vitality. Patients also exhibited greater 
levels of anxiety, depression and somatization. Use of mineralocorticoid receptor 
antagonists was associated with reduced HRQoL. Despite sparse direct economic 
data on MES, hypertension and oedema were associated with increased health 
care resources and costs. Chronic oedema was additionally associated with hospi-
talisation and lost productivity. ConClusions: MES symptoms can significantly 
impair HRQoL and may increase resource use. The impact of these symptoms in an 
advanced prostate cancer population is likely to be exacerbated, as many of these 
elderly patients already have serious co-morbidities. Further research is required 
to determine the incidence and severity of MES in patients receiving abiraterone in 
actual clinical practice and the impact these symptoms have on health care resource 
use and the well-being of patients with prostate cancer.
PCN2
BisPhosPhoNates-assoCiated osteoNeCrosis of Jaw iN CaNCer 
PatieNts: a meta-aNalysis
Lin H.C.1, Lin S.J.1, Chan A.L2
1Kaohsiung Medical University, Kaohsiung, Taiwan, 2Min-Sheng General Hospital, Taoyuan, 
Taiwan
objeCtives: This meta-analysis aims to assess the incidence of osteonecrosis of 
the jaw(ONJ)associated with bisphosphonates in cancer patients. Methods: The 
published literature was systematically searched and reviewed using MEDLINE and 
the Cochrane Central Register of Controlled Trials on 30 April 2013. Any randomized 
controlled trial assessing the role of bisphosphonates in cancer patients and clearly 
mentioned the event of ONJ were eligible for inclusion. Studies that included spe-
cific risk estimates were pooled using a random-effects model. The quality of these 
studies were assessed with RevMan statistical software (version 5.0). Results: 
Eight of 21 randomized controlled clinical trials were included. Thirteen studies 
were excluded due to no cases of osteonecrosis of jaw were reported. A total of 
13,399 patients were collected in eight studies, 6686 patients were assigned to bis-
phosphonates group and 6713 were assigned to control group. Twenty-eight cases 
(28/6686,0.42%) of ONJ were reported in bisphosphonates group. No patient was 
reported in control group. Risk ratio was used to estimate the risk of osteonecrosis 
of the jaw associated with bisphosphonate. Pooled results showed very lower risk 
of ONJ associated with bisphosphonates 5.61 (95% CI: 1.90, 16.52). No heterogeneity 
was found in our study. ConClusions: Although the risk ratio of ONJ associated 
with the use of bisphosphonates is low in our study, we still need to suggest physi-
cians to make a particular concern on using bisphosphonates in cancer patients. We 
suggest that a large and well design of risk of ONJ as primary endpoint, prospective 
multi-center studies should be conducted in the future.
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objeCtives: Patients with mCRPC are at risk of experiencing skeletal-related events 
(SREs), defined as pathologic fracture, spinal cord compression, and the need for radio-
therapy or surgery to bone. We examined the immediate impact of an SRE on patients’ 
HRQoL. Methods: Data were obtained from the AFFIRM study, a phase 3 trial of 
enzalutamide vs. placebo in patients with mCRPC. Only patients experiencing any type 
of SRE were included in the analysis (n= 284). For patients with multiple SREs, only the 
first event was used. HRQoL was assessed at baseline and at fixed intervals throughout 
the study until treatment discontinuation using the FACT-P (Functional Assessment of 
Cancer Therapy–Prostate) instrument. We used linear mixed-effects models to model 
each patient’s longitudinal trajectory of FACT-P outcomes before the first SRE and to 
estimate how far the post-SRE value of HRQoL deviated from that trajectory. Results: 
SREs were associated with a deterioration of HRQoL with an adjusted mean change of 
-6.93 (95% CI: [-9.92; -3.95]) of the FACT-P total score for any SRE. The largest impact was 
observed in subjects with spinal cord compression, which induced a mean decrease 
